Kevin Krenitsky

Dr. Krenitsky is a recognized authority in global diagnostic and biotechnology operations with more than 20 years of senior leadership experience. He was Chief Operating Officer, and later Chief Commercial Officer of Foundation Medicine, a molecular information company dedicated to transforming cancer treatment through enhanced understanding of genomic changes that contribute to a patient’s unique cancer. He helped build the company to a successful IPO, followed by a $1.2B investment by Roche, leading to a full acquisition.

Previously, he served as President of Enzo Clinical Labs and instituted a strategic plan to launch numerous FDA-approved esoteric tests. He served as CEO at both BioServe Biotechnologies, a global biotechnology company, and Parkway Clinical Laboratories, a clinical diagnostic lab. He also has held senior-level positions with Genomics Collaborative, Inc., a clinical and genomics research company.

Dr. Krenitsky received a Bachelor of Science in Business Management from the University of Scranton and a Medical Degree from Jefferson Medical College, Philadelphia. He currently serves on the Board of Directors of several life science companies, including Lumicell, a technology leader developing systems to enable surgeons to see residual cancer cells in the cavity walls in real-time during surgery.